Your request has been received, and our team is working diligently to process it promptly. We understand the importance of timely responses, and we will do our utmost to get back to you as soon as possible.

Click Continue below to leave the current site and be taken to a site maintained by a third party who is solely responsible for its content. Dermavant is providing this link to you only as a convenience; its inclusion does not imply the endorsement of the linked site by Dermavant.

Thank you for signing up. You’ll be hearing from us soon.

Send your patients a link to get started with the MyVTAMA™ Savings Program^†

*Required field

Your Name* Please enter your name

Your Email Address* Please enter your email

Patient's Name* Please enter your patient's name

Patient's Email Address* Please enter your patients email

^†Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.

By submitting this form, I acknowledge that I am a US healthcare professional and give permission for a Dermavant Sciences representative to contact me by phone, email, or text message. Please check above to give consent

By submitting this form, I agree to the Privacy Notice and Terms of Use.

Submit

Sign up now to be among the healthcare professionals to learn more about the latest data, insights, and expert perspectives on VTAMA® (tapinarof) cream, 1%.

*Required field

First Name* Please enter a first name

Last Name* Please enter a last name

ZIP Code* Please enter a ZIP Code

Email Address* Please enter a valid email address

Specialty* Choose... Allergist/Immunologist Dermatologist Dermatology Nurse Practitioner Dermatology Physician Assistant Pediatric Dermatologist Primary Care Physician Primary Care Nurse Practitioner Primary Care Physician Assistant Other Please select a specialty

By entering my email I agree to allow Dermavant Sciences, Inc., and companies working on its behalf, to use this information to contact me about health and product-related information and services associated with plaque psoriasis and atopic dermatitis, and other products. Please check above to give consent

By submitting this form, I agree to the Privacy Notice and Terms of Use.

Submit

Please provide your NPI and contact information below if you would like a Dermavant Sciences sales representative in your region to contact you or if you would like to request samples of VTAMA® (tapinarof) cream, 1%^†

*Required field

I'm primarily interested in the following*

Select one Talking to a sales representative about VTAMA cream Requesting samples of VTAMA cream^† Learning more about events and speakers programs Please select one

National Provider Identifier (NPI)*

Please enter a valid NPI number

Forgot NPI? Find it here

Specialty

Select one Allergy/Immunology Allergy/Immunology Nurse Practitioner Allergy/Immunology Physician Assistant Dermatologist Dermatology Nurse Practitioner Dermatology Physician Assistant Pediatric Dermatologist Primary Care Physician Primary Care Nurse Practitioner Primary Care Physician Assistant Other Please select one

First Name*

Please enter a first name

Last Name*

Please enter a last name

Institution Name

ZIP Code*

Please enter a ZIP code

Email Address*

Please enter a valid email address

Phone Number

^†Please note that sample requests are subject to qualification. We review each request carefully and strive to accommodate qualified professionals. Thank you for your understanding.

By submitting this form, I acknowledge that I am a US healthcare professional and give permission for a Dermavant Sciences sales representative to contact me by phone, email, or text message. Please check above to give consent

Our Privacy Policy further governs the use of the information you provide. By providing the information and selecting the Submit button, you indicate that you read, understand, and agree to these terms.

Submit

References: 1. VTAMA (tapinarof) cream, 1%. Prescribing Information. Dermavant; 2024. 2. Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457-465. 3. Simpson E, Silverberg JI, Bissonnette R, et al. Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to 2 years of age with moderate to severe atopic dermatitis. Oral presentation at: European Academy of Dermatology and Venereology; October 11-14, 2023; Berlin, Germany. 4. Dermavant DOF [ADORING 1&2 Pooled Posthoc; Jan 2025]. 5. Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, treatment response off-therapy, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 trial in adults and children down to 2 years of age with atopic dermatitis. Poster presented at: Fall Clinical Dermatology Conference; October 24-27, 2024; Las Vegas, NV. 6. Stein Gold L, Del Rosso J, Ehst BD, et al. Tapinarof cream 1% once daily was well tolerated for the treatment of adults and children down to 2 years of age with moderate to severe atopic dermatitis across two pivotal phase 3 trials. Poster presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA. 7. Dermavant DOF. ADORING Patient Images. 2024. 8. Dermavant DOF. DMVT-505-3103. 2024. 9. Hebert AA, Del Rosso J, Johnson SM, et al. Patient and parent/caregiver satisfaction with efficacy and cosmetic elegance of tapinarof cream 1% once daily in a long-term extension trial in adults and children down to age 2 years with atopic dermatitis. Poster presented at: Fall Clinical Dermatology Conference; October 24-27, 2024; Las Vegas, NV. 10. Silverberg JI, Boguniewicz M, Quintana FJ, et al. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review. J Allergy Clin Immunol. 2024;154(1):1-10. 11. Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110-2119. 12. Sutter CH, Azim S, Wang A, et al. Ligand activation of the aryl hydrocarbon receptor upregulates epidermal uridine diphosphate glucose ceramide glucosyltransferase and glucosylceramides. J Invest Dermatol. 2023;143(10):1964-1972. 13. Dermavant DOF. The effect of GSK2894512 on the Th2 polarization of human CD4+  T cells and on IL-8 release from TLR2-stimulated keratinocytes. 2015. 14. Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012;166(4):853-860.